This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loeffler, M. Articles by Reisfeld, R. A. Search for Related Content PubMed PubMed Citation Articles by Loeffler, M. Articles by Reisfeld, R. A.

Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase

Department of Immunology, The Scripps Research Institute, La Jolla, California

Requests for reprints: Ralph A. Reisfeld, Department of Immunology, The Scripps Research Institute, IMM13, R218, La Jolla, CA 92037. Phone: 858-784-8105; Fax: 858-784-2708; E-mail: reisfeld{at}scripps.edu.

Cyclophosphamide is a widely used chemotherapeutic drug that was recently applied as either an antiangiogenic/antivasculogenic or an immunostimulatory agent in combination with cancer immunotherapies. It has been previously shown that cyclophosphamide augments the efficacy of antitumor immune responses by depleting CD4⁺CD25⁺ T regulatory cells and increasing both T-lymphocyte proliferation and T memory cells. Furthermore, cyclophosphamide was shown to mediate killing of circulating endothelial progenitors. However, the molecular basis for these observations has not yet been elucidated. We show here that the cyclophosphamide-mediated inhibition of inducible nitric oxide synthase is directly linked to its immunostimulatory but not to its antivasculogenic effects. Moreover, combined application of cyclophosphamide with a novel, oral DNA vaccine targeting platelet-derived growth factor B (PDGF-B), overexpressed by proliferating endothelial cells in the tumor vasculature, not only completely inhibited the growth of different tumor types but also led to tumor rejections in mice. These findings provide a new rationale at the molecular level for the combination of chemotherapy and immunotherapy in cancer treatment.

This article has been cited by other articles:

				S. Rahman, B. Gudetta, J. Fink, A. Granath, S. Ashenafi, A. Aseffa, M. Derbew, M. Svensson, J. Andersson, and S. G. Brighenti Compartmentalization of Immune Responses in Human Tuberculosis: Few CD8+ Effector T Cells but Elevated Levels of FoxP3+ Regulatory T Cells in the Granulomatous Lesions Am. J. Pathol., June 1, 2009; 174(6): 2211 - 2224. [Abstract] [Full Text] [PDF]

				A. P. Castano, P. Mroz, M. X. Wu, and M. R. Hamblin Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model PNAS, April 8, 2008; 105(14): 5495 - 5500. [Abstract] [Full Text] [PDF]

				F. Jadu, L. Lee, M. Pharoah, D. Reece, and L. Wang A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients Ann. Onc., December 1, 2007; 18(12): 2015 - 2019. [Abstract] [Full Text] [PDF]

				S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338. [Abstract] [Full Text] [PDF]